Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated:  4/26/2017
The Mayo Clinic
mi
from
Rochester, MN
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated: 4/26/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated:  4/26/2017
St. Louis University
mi
from
Saint Louis, MO
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated: 4/26/2017
St. Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated:  4/26/2017
New York Univ. Medical Center
mi
from
New York, NY
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated: 4/26/2017
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated:  4/26/2017
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy
Status: Enrolling
Updated: 4/26/2017
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
A Phase 1 Study Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Status: Enrolling
Updated:  4/26/2017
CMHC, Substance Abuse Center
mi
from
New Haven, CT
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
A Phase 1 Study Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Status: Enrolling
Updated: 4/26/2017
CMHC, Substance Abuse Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Acamprosate in Youth With Fragile X Syndrome
Pilot Study of Acamprosate in Youth With Fragile X Syndrome
Status: Enrolling
Updated:  4/27/2017
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children
mi
from
Indianapolis, IN
Acamprosate in Youth With Fragile X Syndrome
Pilot Study of Acamprosate in Youth With Fragile X Syndrome
Status: Enrolling
Updated: 4/27/2017
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Sequenced Therapies for Comorbid and Primary Insomnias
Sequenced Therapies for Comorbid and Primary Insomnias
Status: Enrolling
Updated:  4/27/2017
National Jewish Health
mi
from
Denver, CO
Sequenced Therapies for Comorbid and Primary Insomnias
Sequenced Therapies for Comorbid and Primary Insomnias
Status: Enrolling
Updated: 4/27/2017
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Sequenced Therapies for Comorbid and Primary Insomnias
Sequenced Therapies for Comorbid and Primary Insomnias
Status: Enrolling
Updated:  4/27/2017
Université Laval
mi
from
Quebec City,
Sequenced Therapies for Comorbid and Primary Insomnias
Sequenced Therapies for Comorbid and Primary Insomnias
Status: Enrolling
Updated: 4/27/2017
Université Laval
mi
from
Quebec City,
Click here to add this to my saved trials
Stress, Distress Intolerance, and Drug Dependence
Stress, Distress Intolerance, and Drug Dependence
Status: Enrolling
Updated:  4/28/2017
Habit Management Institute
mi
from
Boston, MA
Stress, Distress Intolerance, and Drug Dependence
Stress, Distress Intolerance, and Drug Dependence
Status: Enrolling
Updated: 4/28/2017
Habit Management Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Stress, Distress Intolerance, and Drug Dependence
Stress, Distress Intolerance, and Drug Dependence
Status: Enrolling
Updated:  4/28/2017
Bay Cove Treatment Center
mi
from
Boston, MA
Stress, Distress Intolerance, and Drug Dependence
Stress, Distress Intolerance, and Drug Dependence
Status: Enrolling
Updated: 4/28/2017
Bay Cove Treatment Center
mi
from
Boston, MA
Click here to add this to my saved trials
Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women
Cognitive Processing Intervention for HIV/STI and Substance Use Among Native Women
Status: Enrolling
Updated:  5/1/2017
Yakama Nation Behavioral Health and Comprehensive Community Alcoholism Program and Youth Treatment Program
mi
from
Toppenish, WA
Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women
Cognitive Processing Intervention for HIV/STI and Substance Use Among Native Women
Status: Enrolling
Updated: 5/1/2017
Yakama Nation Behavioral Health and Comprehensive Community Alcoholism Program and Youth Treatment Program
mi
from
Toppenish, WA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Southern California Research
mi
from
Beverly Hills, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Southern California Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Pharmacology Research Institute
mi
from
Encino, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Synergy Clinical Research of Escondido
mi
from
Escondido, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Synergy Clinical Research of Escondido
mi
from
Escondido, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Excell Research, Inc.
mi
from
Oceanside, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Broward Research Group
mi
from
Hollywood, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Broward Research Group
mi
from
Hollywood, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Geroge M. Joseph MD, PA
mi
from
Jacksonville Beach, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Geroge M. Joseph MD, PA
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Compass Research North, LLC
mi
from
Leesburg, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Compass Research North, LLC
mi
from
Leesburg, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Acumentality
mi
from
Melbourne, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Acumentality
mi
from
Melbourne, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Stedman Clinical Trials
mi
from
Tampa, FL
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
iResearch Atlanta LLC
mi
from
Decatur, GA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
iResearch Atlanta LLC
mi
from
Decatur, GA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Carman Research
mi
from
Smyrna, GA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Alpine Clinic
mi
from
Lafayette, IN
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Alpine Clinic
mi
from
Lafayette, IN
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Psychiatric Associates
mi
from
Overland Park, KA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Psychiatric Care and Research Center
mi
from
O'Fallon, MO
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Psychiatric Care and Research Center
mi
from
O'Fallon, MO
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Premeir Psychiatric Research Institute, LLC
mi
from
Lincoln, NE
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Premeir Psychiatric Research Institute, LLC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Bioscience Research, Llc
mi
from
Mount Kisco, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Bioscience Research, Llc
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Fieve Clinical Research
mi
from
New York, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Fieve Clinical Research
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Medical & Behavioral Health Research
mi
from
New York, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Medical & Behavioral Health Research
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
Medical & Behavioral Health Research
mi
from
New York, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
Medical & Behavioral Health Research
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
NYU School of Medicine
mi
from
New York, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/1/2017
The Medical Research Network, LLC
mi
from
New York, NY
Open-label Safety Study in Adults With ADHD
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/1/2017
The Medical Research Network, LLC
mi
from
New York, NY
Click here to add this to my saved trials